This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
cancer: Archive
BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers Squibb's Growth Portfolio and pipeline support momentum, but generic headwinds and recent gains call for a cautious stance.
BMYNegative Net Change PFENegative Net Change MRKPositive Net Change
biotechnology biotechs cancer medical pharmaceuticals
UnitedHealth vs. Centene: Which Managed Care Stock Is the Better Buy?
by Rajshree Sipani
UNH's diversified platform, AI expansion and Optum momentum strengthen its long-term outlook, making it the stronger managed care pick over CNC.
UNHPositive Net Change CNCPositive Net Change
artificial-intelligence automation cancer healthcare hmo hospitals insurance insurance-premium medical pharmaceuticals smart-health staffing
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
by Debanjana Dey
bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in.
BDSXPositive Net Change BIAFPositive Net Change
biotechnology biotechs cancer medical oncology-screening
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
by Debanjana Dey
Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.
CSBRNegative Net Change CTKBNegative Net Change
biotechnology biotechs cancer medical oncology-screening
2 Microcaps With Gross Margin Catalysts
by Mark Zinski
CSBR and CEPL have levers in place for Gross Margin improvement.
CSBRNegative Net Change CEPLNegative Net Change
cancer energy healthcare utilities
AWHL vs. MYGN: Which Women's Health Diagnostics Stock is Better Now?
by Debanjana Dey
Aspira and Myriad Genetics take different approaches to women's health diagnostics, but which stock looks more compelling now? Let's dive in.
MYGNNegative Net Change AWHLNegative Net Change
biotechnology biotechs cancer medical medical-devices oncology-screening
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?
by Debanjana Dey
Precipio and NeoGenomics take different approaches to cancer diagnostics, but which oncology stock looks more compelling now? Let's dive in.
NEONegative Net Change PRPOPositive Net Change
cancer medical oncology-screening
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
by Kinjel Shah
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
AUTLNegative Net Change NXTCNegative Net Change RXRXNegative Net Change AZNNegative Net Change NVSNegative Net Change JNJNegative Net Change PFENegative Net Change
cancer pharmaceuticals
4 Biotech Stocks Investors Should Watch in 2026
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
LQDAPositive Net Change STOKNegative Net Change IMNMPositive Net Change IMCRPositive Net Change
biotechnology biotechs cancer medical pharmaceuticals
Cancer Stocks That Are Advancing the Future of Oncology Care
by Kinjel Shah
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
AZNNegative Net Change NVSNegative Net Change JNJNegative Net Change PFENegative Net Change VSTMNegative Net Change SMMTNegative Net Change XLOPositive Net Change
cancer pharmaceuticals